Magellan Diagnostics, Inc. Expands Voluntary Recall of LeadCare® Test Kits

If your email program has trouble displaying this email, view as a webpage. Magellan Diagnostics, Inc. Expands Voluntary Recall of LeadCare® Test Kits Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced its wholly owned subsidiary, Magellan Diagnostics, Inc. ("Magellan"), expanded the Class I recall of its LeadCare® II Blood Lead Test Kits, LeadCare Plus® Blood Lead Test Kits, and LeadCare Ultra® Blood Lead Test Kits (the "LeadCare Test Kits") for the detection of lead in whole blood. Magellan provides two controls in the test kits which are designed to mimic blood and are spiked with lead to specific target values with an associated acceptable range.  Results of the control tests within the acceptable range indicate that the system is operating properly before testing patient samples.  In May 2021, Magellan initiated this voluntary recall after identifying an ongoing issue with testing of the controls included in the LeadCare Test Kits.  Magellan continues to investigate this issue and has conducted extensive testing to evaluate potential root causes.

Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA